【摘要】 目的 系统评价中药联合灸法(灸药结合)对肿瘤化疗患者骨髓抑制的防治作用。方法 计算机检索从建库至2025年7月，在PubMed、Cochrane Library、Web of Science、CNKI、万方、维普等数据库，收集以中药联合灸法为干预措施防治肿瘤化疗骨髓抑制的随机对照实验(randomized controlled trial, RCT),采用Cochrane5.1.0偏倚风险评估工具进行文献质量评价，Revman 5.4软件进行Meta分析。结果 纳入文献19篇，共计1545例研究对象，其中实验组771例，对照组774例。Meta分析结果显示，与单纯化疗相比，灸药结合可以降低白细胞减少率[RR=0.27,95%CI(0.18,0.40),P<0.00001]、降低血小板减少率[RR=0.28,95%CI(0.18,0.44),P<0.00001]、升高血细胞计数[白细胞计数MD=0.99,95%CI(0.72,1.26),P<0.00001;血小板计数MD=21.14,95%CI(16.59,25.68),P<0.00001;血红蛋白计数MD=9.12,95%CI(5.54,12.70),P<0.00001]、提高KPS评分[MD=6.09,95%CI(2.02,10.17),P=0.003]、提高临床疗效[RR=2.50,95%CI(1.67,3.76),P<0.00001]、缓解恶心呕吐症状[RR=0.25,95%CI(0.18,0.35),P<0.00001]、缓解肝肾功能损害[RR=0.36,95%CI(0.23,0.55),P<0.00001]。结论 相较于单纯化疗，灸药结合对肿瘤化疗患者骨髓抑制具有较好的有效性及安全性，但因为纳入的研究较少，质量有限，还有待更多大样本、高质量、多中心的研究以验证。更多还原

【Abstract】 Objective To systematically evaluate the preventive and therapeutic effects of Traditional Chinese Medicine(TCM) combined with moxibustion in tumor patients with chemotherapy-induced myelosuppression(CIM).Methods Computerized searches were conducted from database establishment to July 2025 in PubMed, Cochrane library, Web of Science, CNKI,Wanfang Database, VIP Database(VIP),China Biomedical Literature Database(CBM) and China Clinical Trial Registration Center( ChiCTR) to collect clinical randomized controlled trials(RCTs) of TCM combined with moxibustion in the prevention and treatment of tumor patients with CIM.The search time was from the establishment of the database to July 2025.Cochrane 5.1.0 bias risk assessment tool was used to evaluate the methodological quality, and RevMan 5.4 software was used for Meta analysis.Results A total of 19 articles were included in this meta-analysis, comprising 1545 participants, with 771 cases in the experimental group and 774 cases in the control group.Meta-analysis showed that compared with chemotherapy alone, TCM combined with moxibustion significantly reduced the leukopenia rate[RR=0.27,95% CI(0.18,0.40),P<0.00001] and thrombocytopenia rate[RR=0.28,95% CI(0.18,0.44),P<0.00001],elevated blood cell counts[white blood cell count: MD=0.99,95% CI(0.72,1.26),P<0.00001;platelet count: MD=21.14,95% CI(16.59,25.68),P<0.00001;hemoglobin count: MD=9.12,95% CI(5.54,12.70),P<0.00001],improved KPS score[MD=6.09,95%CI(2.02,10.17),P=0.003],enhanced clinical efficacy[RR=2.50,95% CI(1.67,3.76),P<0.00001],alleviated nausea and vomiting symptoms[RR=0.25,95% CI(0.18,0.35),P<0.00001],and alleviated hepatic and renal impairment[RR=0.36,95% CI(0.23,0.55),P<0.00001].Conclusions Compared with chemotherapy alone, TCM combined with moxibustion demonstrates better efficacy and safety for CIM.However, further large-sample, high-quality, multicenter studies are warranted due to the limited number and quality of included studies.更多还原